MX2009001015A - Anticuerpos modificadores de enfermedad cancerosa. - Google Patents
Anticuerpos modificadores de enfermedad cancerosa.Info
- Publication number
- MX2009001015A MX2009001015A MX2009001015A MX2009001015A MX2009001015A MX 2009001015 A MX2009001015 A MX 2009001015A MX 2009001015 A MX2009001015 A MX 2009001015A MX 2009001015 A MX2009001015 A MX 2009001015A MX 2009001015 A MX2009001015 A MX 2009001015A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- cancer
- disease modifying
- cancerous disease
- modifying antibodies
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000001093 anti-cancer Effects 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000013210 hematogenous Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
Abstract
La presente invención se refiere a un método para producir anticuerpos modificadores de enfermedad cancerosa en un paciente utilizando un novedoso paradigma de detección. Mediante la segregación de los anticuerpos anticancerosos usando citotoxicidad de células de cáncer como objetivo, el proceso hace posible la producción de anticuerpos anticancerosos para propósitos terapéuticos y de diagnóstico. Los anticuerpos pueden utilizarse como auxiliares para determinar la fase y para el diagnóstico de un cáncer, y se pueden utilizar para tratar tumores primarios y metástasis tumoral. Los anticuerpos anticancerosos pueden ser conjugados con toxinas, enzimas, compuestos radiactivos, y células hematógenas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83343106P | 2006-07-26 | 2006-07-26 | |
PCT/CA2007/001318 WO2008011711A1 (en) | 2006-07-26 | 2007-07-24 | Cancerous disease modifying antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009001015A true MX2009001015A (es) | 2009-06-22 |
Family
ID=38981089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009001015A MX2009001015A (es) | 2006-07-26 | 2007-07-24 | Anticuerpos modificadores de enfermedad cancerosa. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080089891A1 (es) |
EP (1) | EP2044119A4 (es) |
JP (1) | JP2009545528A (es) |
KR (1) | KR20090059106A (es) |
CN (1) | CN101547936A (es) |
AU (1) | AU2007278792A1 (es) |
BR (1) | BRPI0715544A2 (es) |
CA (1) | CA2666515A1 (es) |
MX (1) | MX2009001015A (es) |
NO (1) | NO20090342L (es) |
RU (1) | RU2009104624A (es) |
WO (1) | WO2008011711A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2825553B1 (en) * | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
KR20200015932A (ko) | 2017-06-07 | 2020-02-13 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화를 위한 조성물 및 방법 |
WO2022053985A1 (en) | 2020-09-10 | 2022-03-17 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 antibodies and methods of use thereof |
IL307328A (en) * | 2021-03-29 | 2023-11-01 | Vascular Biogenics Ltd | MOTILE SPERM DOMAIN CONTAINING PROTEIN 2, INTEGRIN BETA2 and CD63 |
KR102627688B1 (ko) | 2021-11-09 | 2024-01-23 | 호서대학교 산학협력단 | 죽단화 꽃 에센셜오일을 유효성분으로 포함하는 피부 재생 및 주름 개선용 화장료 조성물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4828991A (en) * | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
AU613590B2 (en) * | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US5296348A (en) * | 1989-05-16 | 1994-03-22 | The Wistar Institute Of Anatomy And Biology | Methods for screening monoclonal antibodies for therapeutic use |
US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
EP0539970B1 (en) * | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
IL105008A0 (en) * | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
ATE244888T1 (de) * | 1993-02-05 | 2003-07-15 | Epigen Inc | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
ES2150573T3 (es) * | 1994-06-24 | 2000-12-01 | Vladimir P Torchilin | Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales. |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
WO1999066027A1 (en) * | 1998-06-15 | 1999-12-23 | The Research Foundation Of State University Of New York | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
US20040105816A1 (en) * | 1999-10-08 | 2004-06-03 | Young David S. F. | Cancerous disease modifying antibodies |
US6657048B2 (en) * | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US7256271B2 (en) * | 2003-01-21 | 2007-08-14 | Arius Research Inc. | Cancerous disease modifying antibodies |
US20020102638A1 (en) * | 2000-01-31 | 2002-08-01 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US7279294B2 (en) * | 2000-04-03 | 2007-10-09 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih | Tumor markers in ovarian cancer |
US20060210474A1 (en) * | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7431923B2 (en) * | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
WO2002057303A2 (en) * | 2001-01-12 | 2002-07-25 | Hybrigenics | Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides |
US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
WO2002086069A2 (en) * | 2001-04-20 | 2002-10-31 | Incyte Genomics, Inc. | Secreted proteins |
DE60238143D1 (de) * | 2001-09-18 | 2010-12-09 | Genentech Inc | Zusammensetzungen und verfahren für die diagnose von tumoren |
EP1455819A1 (en) * | 2001-12-21 | 2004-09-15 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
-
2007
- 2007-07-23 US US11/880,619 patent/US20080089891A1/en not_active Abandoned
- 2007-07-24 AU AU2007278792A patent/AU2007278792A1/en not_active Abandoned
- 2007-07-24 RU RU2009104624/10A patent/RU2009104624A/ru unknown
- 2007-07-24 EP EP07784985A patent/EP2044119A4/en not_active Withdrawn
- 2007-07-24 BR BRPI0715544-1A2A patent/BRPI0715544A2/pt not_active Application Discontinuation
- 2007-07-24 CN CNA200780030641XA patent/CN101547936A/zh active Pending
- 2007-07-24 WO PCT/CA2007/001318 patent/WO2008011711A1/en active Application Filing
- 2007-07-24 CA CA002666515A patent/CA2666515A1/en not_active Abandoned
- 2007-07-24 MX MX2009001015A patent/MX2009001015A/es not_active Application Discontinuation
- 2007-07-24 JP JP2009521074A patent/JP2009545528A/ja active Pending
- 2007-07-24 KR KR1020097001773A patent/KR20090059106A/ko not_active Application Discontinuation
-
2009
- 2009-01-22 NO NO20090342A patent/NO20090342L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101547936A (zh) | 2009-09-30 |
WO2008011711A1 (en) | 2008-01-31 |
BRPI0715544A2 (pt) | 2014-10-29 |
AU2007278792A1 (en) | 2008-01-31 |
US20080089891A1 (en) | 2008-04-17 |
EP2044119A4 (en) | 2010-09-01 |
NO20090342L (no) | 2009-04-27 |
JP2009545528A (ja) | 2009-12-24 |
CA2666515A1 (en) | 2008-01-31 |
EP2044119A1 (en) | 2009-04-08 |
RU2009104624A (ru) | 2010-09-10 |
KR20090059106A (ko) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1718737T1 (sl) | Protitelesa ki modificirajo rakovo obolenje | |
WO2007095749A8 (en) | Cytotoxicity mediation of cells evidencing surface expression of trop-2 | |
MX2009007619A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
CY1106455T1 (el) | Τροποποιητικα αντισωματα καρκινικης νοσου | |
MX2009001015A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
WO2004065422A3 (en) | Cancerous disease modifying antibodies | |
BRPI0601736A (pt) | métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais | |
MX2009007618A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
MX2009007617A (es) | Anticuerpos modificadores de una enfermedad cancerigena. | |
WO2005012361A3 (en) | Antibodies raised against colon carcinomas | |
WO2003086456A3 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer | |
GB0718878D0 (en) | Photodynamic Theraphy and diagnosis | |
EP1929034A4 (en) | ANTIBODIES CAPABLE OF MODIFYING EVOLUTION OF CANCER DISEASE | |
MX2009011667A (es) | Anticuerpos de modificacion de enfermedad cancerosa. | |
MX2009001292A (es) | Anticuerpos modificadores de enfermedad cancerosa. | |
MX2009009919A (es) | Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma. | |
MX2009009533A (es) | Conjugados de hidroxipolimero modificado con efecto letal en celulas tumorales. | |
WO2008058380A8 (en) | Cancerous disease modifying antibodies | |
NO20091459L (no) | Cancerose sykdomsmodifiserende antistoffer | |
DK1360208T3 (da) | Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer | |
BRPI0718609A8 (pt) | Anticorpos modificadores de doença cancerosa. | |
AR070279A1 (es) | Anticuerpos modificadores de enfermedades cancerosas (cdma) | |
WO2010028820A3 (en) | Peripheral zone tumor cells, methods for their preparation and use | |
AR072750A1 (es) | Anticuerpos modificadores de enfermedades cancerosas | |
AR070280A1 (es) | Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |